Register
CVOTs with GLP-1 Receptor Agonists: How Significant? |
Conferences
eMediNexus Coverage from:  RSSDI 2018
CVOTs with GLP-1 Receptor Agonists: How Significant?
Dr Ajay Kumar, Patna,  27 November 2018
remove_red_eye 615 Views
#Cardiology #Diabetes and Endocrinology

0 Read Comments                

GLP-1 may affect cardiac function indirectly through its actions on pancreatic islets to increase insulin secretion and inhibit glucagon secretion. Evidence points to a reduction in systolic BP with GLP-1 RAs. GLP-1 RAs also improve CV-risk biomarkers.Several CVOTs have been conducted with GLP-1 RAs and some are still underway. In the LEADER trial, in the time-to-event analysis, the rate of the first occurrence of CV dea
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!